Pharmacy evidence record · researched 2026-08-20
Pharmcore, Inc. dba Hallandale Pharmacy
The current product page lists multiple injectable Semaglutide Flex-Dose strengths and volumes.
The current product page lists multiple injectable Tirzepatide Flex-Dose strengths and volumes.
Product-page presence does not establish availability in every state or for every patient.
Regulatory compliance
A pathway label describes which federal rules apply — it is not a quality claim.
Section 503A
Hallandale describes itself as a 503A pharmacy. FDA's compounding-action index also labels the facility type 503A. Section 503A is a statutory compounding pathway, not an FDA facility registration.
Section 503B
No exact Hallandale/Pharmcore match was found in the FDA current registered-outsourcing-facility list checked on 2026-08-20. This is recorded as a bounded registry result, not a categorical claim that no affiliated 503B entity exists.
Telehealth providers
Clinic Scout links a provider only when an explicit source names the relationship.
Regulatory history
FDA warning-letter, Form 483, compounding-action, current 503B-registry, and Florida license sources were checked. Florida's accessible license record showed no discipline on file in the agent result; other state-board action searches were not exhaustively completed.
U.S. Food and Drug Administration · 2020-03-11
FDA stated that investigators observed serious deficiencies in sterile-drug production, insanitary conditions, and drug products that did not meet all conditions of section 503A. FDA later stated that Pharmcore appeared to have adequately addressed the violations in this warning letter.
closed_out_2022-05-03U.S. Food and Drug Administration · 2025-06-13
FDA listed three inspection observations concerning calibration response, complaint review/procedures, and stability/reprocessing support. A Form 483 records inspection observations and is not itself a final agency determination.
issuedNo Clinic Scout patient reviews are published for this pharmacy. Submissions go through manual moderation before anything appears here.
What this record verifies for you
Each line traces to a citation in the source list below — read the exact captured wording before relying on it.
No superiority claim is made for review volume, ratings, or patient sentiment.
Since our establishment in 2004, the growing demand for customized medications has propelled us to deliver an unparalleled pharmacy experience.
As a 503A designated pharmacy, we are held to the standards of USP.
Semaglutide Double-Strength Flex-Dose 3 mL 5 mg/mL Injectable ... Tirzepatide Forte Flex-Dose 4 mL 15 mg/mL Injectable
PHARMCORE, INC. HALLANDALE PHARMACY COMPOUNDING License Number: PH28017
During the inspection, the FDA investigators observed serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.
Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
OBSERVATION 2 Procedures for the receipt and evaluation of complaints concerning drug products are not adequate.
Updated as of 8/18/2026 ... This table lists the outsourcing facilities that have submitted registration information that has been determined to be complete by the data lock date for the latest weekly update of the table.
GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 8 dated first-party or regulator citation(s), 2 regulatory/action record(s), and 3 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.
Weekly price watch
One useful comparison each week. No spam, no sold lists, and you can unsubscribe anytime.